3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
37
Advanced Breast Cancer
5
Neoplasm Metastasis
4
Neoplasms
2
The Neoadjuvant Therapy
1
Solid Tumor, Adult
1
Recurrent Uterine Corpus Carcinoma
1
Hormone Receptor-positive Advanced Breast Cancer
1
Hormone Receptor Positive Advanced Breast Cancer
1
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
1
HR Positive/HER-2 Negative Breast Cancer
1
Estrogen Receptor-positive Breast Cancer
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Breast Neoplasm Female
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Breast Cancer Organoids
1
Brain Neoplasms
1
Interventions
sotorasib
1
abemaciclib
1
X-Rays
1
Trastuzumab
1
Rosuvastatin Calcium
1
Rifampin
1
Pharmaceutical Services
1
Midazolam
1
Itraconazole
1
Injections
1
High-Throughput Nucleotide Sequencing
1
Fulvestrant
1
Digoxin
1
Dextromethorphan
1
Data Collection
1
Catalytic Domain
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Solid Tumor, Adult
×
Fulvestrant
×
Clear all
NCT04092673
2024-05-21
Zotatifin
Effector Therapeutics
Phase 1/2
Unknown
30 enrolled